Evidence map›Paper›PMID 38665914›Full record

ArticleFrontiers in immunology2024

Case report: Atypical case of autoimmune glial fibrillary acidic protein astrocytopathy following COVID-19 vaccination refractory to immunosuppressive treatments.

Yuto Morishima, Takanori Hata, Sho Nakajima, Kazumasa Shindo, Mai Tsuchiya, Tsubasa Watanabe, Ippei Tahara, Tetsuo Kondo, Akio Kimura, Takayoshi Shimohata and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yuto MorishimaDepartment of Neurology, University of Yamanashi, Chuo, Japan.
Takanori HataDepartment of Neurology, University of Yamanashi, Chuo, Japan.
Sho NakajimaDepartment of Neurology, University of Yamanashi, Chuo, Japan.
Kazumasa ShindoDepartment of Neurology, University of Yamanashi, Chuo, Japan.
Mai TsuchiyaDepartment of Neurology, University of Yamanashi, Chuo, Japan.
Tsubasa WatanabeDepartment of Neurology, University of Yamanashi, Chuo, Japan.
Ippei TaharaDepartment of Pathology, University of Yamanashi, Chuo, Japan.
Tetsuo KondoDepartment of Pathology, University of Yamanashi, Chuo, Japan.
Akio KimuraDepartment of Neurology, Gifu University Graduate School of Medicine, Gifu, Japan.
Takayoshi ShimohataDepartment of Neurology, Gifu University Graduate School of Medicine, Gifu, Japan.
Yuji UenoDepartment of Neurology, University of Yamanashi, Chuo, Japan.
University of Yamanashi · JPGifu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 54-year-old Japanese man presented with headache and fever the day after SARS-CoV-2 vaccination. He became deeply unconscious within a week. Brain MRI showed periventricular linear enhancements and a few spotty lesions in the cerebral white matter. Cerebrospinal fluid (CSF) testing showed mild pleocytosis. He was treated with intravenous methylprednisolone and plasma exchange. However, the white matter lesions enlarged to involve the brainstem and cerebellum, and long cord spinal lesions appeared. Anti-glial fibrillary acidic protein (GFAP) antibody was positive in the CSF and serum, and he was therefore diagnosed as autoimmune GFAP-astrocytopathy (GFAP-A). In addition, high-dose immunoglobulin therapy was administered twice, but his symptoms did not improve; the white matter lesions enlarged further, and modified Rankin Scale score increased to 5. A brain biopsy specimen showed infiltration of macrophages and CD

Indexed as

COVID-19Glial Fibrillary Acidic ProteinSARS-CoV-2AstrocytesAutoantibodiesBrainCOVID-19 VaccinesHumansImmunosuppressive AgentsMaleMiddle AgedVaccinationAutoantibodiesCOVID-19 VaccinesGFAP protein, humanGlial Fibrillary Acidic ProteinImmunosuppressive Agentsanti-GFAP antibodyautoimmune encephalitisCOVID-19 vaccinationGFAP-astrocytopathyimmunosuppressive treatments

Identifiers

PMID38665914
PMCPMC11043467
OpenAlexW4394722799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.